Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808574 | 0.87 | MAPT (0.62) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL29456062 | 0.83 | POLB (0.64) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL933584 | 0.83 | POLB (0.64) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL12661051 | 0.82 | MAPT (0.63) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL3785481 | 0.81 | POLB (0.58) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL5641249 | 0.81 | MAPT (0.58) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL28067863 | 0.80 | MAPT (0.60) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL3783132 | 0.79 | MAPK10 (0.67) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL9801910 | 0.78 | POLB (0.63) | MAPTTP53POLBTHRBLMNA | |
| SCHEMBL6656950 | 0.77 | POLB (0.65) | MAPTTP53POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | MAPT 2216/4885TP53 4151/4885POLB 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.